Loading the company…
Loading the company…
㈜엠에스바이오텍
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Chungbuk, founded in 2000. Industry: Food & Consumer Goods. Revenue for 2025 was ₩43.7bn. It has 92 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2021-04-27 · latest registration 2024-05-17 · newest first
본 발명은 신규한 락토바실러스 퍼멘텀 ATG-V5 균주 또는 이를 포함하는 면역증강용 조성물에 관한 것으로, 본 발명의 락토바실러스 퍼멘텀(Lactobacillus fermentum) ATG-V5 균주는 세포독성이 없고, 대식세포의 NO(Nitric Oxide), IL-6(Interleukin 6) 및 TNF(Tumor Necrosis Factor) 분비량, 및 식세포작용(phagocytosis)을 증가시키고, 대식세포의 IL-1β(Interleukin 1β)의 분비량을 감소시키며, 비장세포의 세포 생존력을 증가시키고, 혈액 내 항체 및 사이토카인 분비량을 증가시키는 등 면역증강 효능이 있으므로, 상기 균주는 면역증강용 약학적 조성물 및 식품 조성물 소재로서 유용하게 사용할 수 있고, 상기 조성물은 개체의 면역 활성을 증진시키는 데 유용하게 사용할 수 있다. 아울러 상기 식품 조성물을 함유하는 것을 특징으로 하는 건강기능식품 또한 개체의 면역 활성 증진에 효과적이다.
본 발명은 폴리감마글루탐산을 다량으로 생산하는 바실러스 서브틸리스 SE-4(Bacillus subtilis SE-4) 및 이의 발효대사물을 포함하는 칼슘 보충용 조성물에 관한 것으로, 본 발명의 조성물은 칼슘의 장내 흡수율을 증진시켜 성장기 어린이 및 청소년의 골격 및 신체성장을 촉진할뿐만 아니라 성장장애를 치료 또는 예방하는 데 유용하게 활용될 수 있다. 바실러스 서브틸리스 SE-4, 발효대사물, 폴리감마글루탐산, 칼슘보충, 성장촉진
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 37.1 | 43.7 |
| Cost of sales | 32.6 | 37.7 |
| Gross profit (loss) | 4.5 | 6.0 |
| Selling, general and administrative expenses | 2.0 | 3.0 |
| Operating income (loss) | 2.5 | 3.0 |
| Non-operating income | 0.3 | 0.3 |
| Other gains | 0.2 | 0.2 |
| Finance income | 0.0 | 0.0 |
| Other | 0.1 | 0.1 |
| Non-operating expenses | 0.3 | 0.3 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.3 | 0.2 |
| Other | 0.1 | 0.1 |
| Profit (loss) before tax | 2.5 | 3.0 |
| Income tax expense | 0.2 | 0.2 |
| Net income (loss) | 2.3 | 2.7 |
Revenue ₩43.7bn, up 17.8% YoY.
Operating margin 6.9% (prior 6.6%).
Net income ₩2.7bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06